Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas

DSpace/Manakin Repository

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas

Citable link to this page


Title: Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
Author: Ren, Yin; Sagers, Jessica E.; Landegger, Lukas D.; Bhatia, Sangeeta N.; Stankovic, Konstantina M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Ren, Yin, Jessica E. Sagers, Lukas D. Landegger, Sangeeta N. Bhatia, and Konstantina M. Stankovic. 2017. “Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.” Scientific Reports 7 (1): 12922. doi:10.1038/s41598-017-13032-9. http://dx.doi.org/10.1038/s41598-017-13032-9.
Full Text & Related Files:
Abstract: Vestibular schwannoma (VS) is the most common tumor of the cerebellopontine angle, and it typically presents with sensorineural hearing loss. The genomic landscape of schwannoma is complex and many of the molecules implicated in VS pathogenesis represent targets not amenable to antibody-based or small molecule therapeutics. Tumor-targeted delivery of small interfering RNA (siRNA) therapeutics provides a direct and effective means to interrogate targets while minimizing off-target effects. To establish a preclinical model for therapeutic inhibition of putative targets in VS, archived tumor specimens, fresh tumor cells derived from patients with sporadic VS, and an established schwannoma cell line were screened. Nanoparticles directed by the tumor-homing peptide iRGD were selectively taken up by primary VS cultures in vitro via interactions with αvβ3/β5 integrins and neuropilin-1 (NRP-1). Cellular uptake was inhibited by a neutralizing antibody against αv integrin in a dose-dependent manner. When applied to primary VS cultures, iRGD-targeted nanoparticles delivered siRNA directed against TNFα in a receptor-specific fashion to potently silence gene expression and protein secretion. Taken together, our results provide a proof of principle for tumor-targeted, nanoparticle-mediated delivery of siRNA to VS and establish a novel platform for the development and pre-clinical screening of molecular therapeutics against VS.
Published Version: doi:10.1038/s41598-017-13032-9
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635039/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492444
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search